A single amino acid mutation alters multiple neutralization epitopes in the respiratory syncytial virus fusion

Ahmed K Oraby1,2,3, Aleksandra Stojic1, Farah Elawar1

  • 1Department of Medical Microbiology and Immunology, Edmonton, AB, Canada.

Npj Viruses
|April 28, 2025
PubMed

Insights

A single mutation in the respiratory syncytial virus fusion glycoprotein (RSV-F) can help the virus evade neutralizing antibodies. This finding is crucial for developing effective RSV vaccines and therapies.

Area of Science:

  • Virology
  • Immunology
  • Structural Biology

Background:

  • Respiratory syncytial virus (RSV) is a major cause of infant hospitalization.
  • Current RSV treatments and vaccines target the highly conserved RSV fusion glycoprotein (RSV-F).
  • Neutralization sites on RSV-F are generally stable and rarely mutate.

Purpose of the Study:

  • To investigate the impact of specific mutations in the RSV-F protein on antibody binding and neutralization.
  • To explore the role of amino acid position 305 in RSV-F's antigenic properties and viral evasion strategies.

Main Methods:

  • In vitro evolution assays to identify common RSV mutations.
  • Computational modeling to predict the structural and antigenic effects of mutations.
  • Screening of published RSV-F sequences to assess mutation prevalence.

Main Results:

  • A single amino acid mutation (L305I) in RSV-F significantly alters antibody binding sites and reduces neutralization susceptibility.
  • The L305I mutation was found in a majority of RSV quasi-species in vitro.
  • Computational models predicted that L305I changes the epitope landscape, affecting antibody affinity and sensitivity.
  • Position 305 is conserved with leucine or isoleucine in RSV-A and RSV-B subtypes.

Conclusions:

  • Specific amino acids in RSV-F can act as 'conformational switches' enabling viral evasion of host antibodies.
  • Mutations distant from antigenic sites can confer resistance to neutralizing antibodies, altering viral sensitivity.
  • Understanding these antigenic landscape changes is vital for developing effective RSV vaccines and therapeutics.